文献速递细菌感染、耐药与抗菌药物

感染部位抗菌药物治疗药物监测的三级模型

A three-level model for therapeutic drug monitoring of antimicrobials at the site of infection.
PubMed 文献 · Lancet Infect Dis · 2023-06-19

本文提出一个用于抗菌药物感染部位治疗药物监测(TDM)的三级模型,将血液药物测定与非侵入性可采集生物流体(如汗液、呼出气)中的药物浓度分析相联系,以表征感染部位的药物浓度,并概述开发用于感染部位应用的可穿戴传感平台所需的临床和技术步骤。

要点

  • 基于血液分析的TDM有助于缓解细菌抗菌药物耐药性的出现,并有效降低患者血液中有毒药物浓度的风险。
  • 危重症或慢性病患者的抗生素组织穿透性可能不同,可能导致治疗失败。
  • 可穿戴传感器的出现使得无需实验室即可分析非侵入性生物流体中的生物标志物和药物。

核心结论

  • 本文提出的三级模型将基于血液的药物测量与非侵入性可采集生物流体(来源于感染部位)中的药物浓度分析相联系,以表征感染部位的药物浓度。
  • 本文概述了开发用于感染部位应用的可穿戴传感平台所需的临床和技术步骤。

研究设计与样本

  • 本文为Personal View,提出一个用于抗菌药物TDM的三级模型,并概述开发可穿戴传感平台所需的临床和技术步骤。

主要发现

  • 基于血液分析的TDM可以帮助缓解细菌抗菌药物耐药性的出现,并有效降低患者血液中有毒药物浓度的风险。
  • 危重症或慢性病患者的抗生素组织穿透性可能不同,可能导致治疗失败。
  • β-内酰胺类和糖肽类等抗生素可在汗液和呼出气等非侵入性可采集生物流体中检测到。
  • 可穿戴传感器的出现使得无需实验室即可分析各种疾病相关生物标志物和药物。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The silent pandemic of bacterial antimicrobial resistance is a leading cause of death worldwide, prolonging hospital stays and raising health-care costs. Poor incentives to develop novel pharmacological compounds and the misuse of antibiotics contribute to the bacterial antimicrobial resistance crisis. Therapeutic drug monitoring (TDM) based on blood analysis can help alleviate the emergence of bacterial antimicrobial resistance and effectively decreases the risk of toxic drug concentrations in patients' blood. Antibiotic tissue penetration can vary in patients who are critically or chronically ill and can potentially lead to treatment failure. Antibiotics such as β-lactams and glycopeptides are detectable in non-invasively collectable biofluids, such as sweat and exhaled breath. The emergence of wearable sensors enables easy access to these non-invasive biofluids, and thus a laboratory-independent analysis of various disease-associated biomarkers and drugs. In this Personal View, we introduce a three-level model for TDM of antibiotics to describe concentrations at the site of infection (SOI) by use of wearable sensors. Our model links blood-based drug measurement with the analysis of drug concentrations in non-invasively collectable biofluids stemming from the SOI to characterise drug concentrations at the SOI. Finally, we outline the necessary clinical and technical steps for the development of wearable sensing platforms for SOI applications.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Brasier N, Ates HC, Sempionatto JR, et al. A three-level model for therapeutic drug monitoring of antimicrobials at the site of infection. Lancet Infect Dis. 2023. PMID: 37348517. doi:10.1016/S1473-3099(23)00215-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。